PD-L1 抑制剂在非小细胞肺癌 治疗中的研究进展

程序性死亡分子配体1（PD-L1）抑制剂等免疫疗法是治疗非小细胞肺癌（NSCLC）的一项重 大进展。但由于缺乏明确的生物标志物来选择最佳的受益人群，因此该抑制剂只在约20% 晚期NSCLC 患者 中起作用。与单药治疗比较，NSCLC 患者结合常规和/ 或靶向治疗显示更好的安全性和疗效。笔者总结几 种已批准用于NSCLC 治疗的抗PD-L1 药物，且强调抗PD-L1 治疗与化学疗法、血管内皮生长因子抑制剂、 靶向治疗，以及放射治疗等其他非免疫治疗相结合的临床研究进展。

Progression on PD-L1 inhibitors in the treatment of non-small cell lung cancer

With the rapid development of tumor immunity, immune therapies such as programmed death ligand-1 (PD-L1) inhibitors play an important role in the treatment of NSCLC. Because of the lack of the definite biomarkers to select the optimal responders, only approximately 20% of patients with advanced NSCLC would respond to single checkpoint inhibitors-based immunotherapy. In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments. In this review article, we summarized several anti-PD-L1 agents licensed for NSCLC treatment, and highlight the clinical progress in the combinatory therapy of anti PD-L1 therapy with chemotherapy, vascular endothelial growth factor inhibitors, targeted therapies, and radiation.